Horizon Pharma

Horizon Therapeutics Plc is a biopharmaceutical company, which is engaged in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Earnings data Q4 2019

Earnings data Q1 2020

Earnings data Q2 2020

Earnings data Q3 2020

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q2 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Horizon Therapeutics Plc is a biopharmaceutical company, which engages in the research, development, and marketing of pharmaceutical products. It operates through the Orphan and Inflammation segments. The Orphan segment consists of medicines KRYSTEXXA, RAVICTI, PROCYSBI, ACTIMMUNE, BUPHENYL, QUINSAIR, and RAYOS. The Inflammation segment comprises medicines PENNSAID 2%, DUEXIS, and VIMOVO. The company was founded in 2008 and is headquartered in Dublin, Ireland.

Horizon Therapeutics (HZNP) reported earnings 30 days ago. What's next for the stock?

Why Is Horizon Therapeutics (HZNP) Up 3.7% Since Last Earnings Report?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that the Company will participate in the following conferences: Handelsbanken Life Science Innovation Day 2021 (Virtual) Date: Wednesday, Aug. 25, 2021 Presentation time: 10 a.m. ET Morgan Stanley 19th Annual Global Healthcare Conference (Virtual) Date: Friday, Sept. 10, 2021 Presentation time: 10:15 a.m. ET The conference presentations will be webcast live and may be accessed by visiting Horizon's website at http:

Horizon Therapeutics plc to Participate in Upcoming Conferences

If you are looking for a fast-growing stock that is still seeing plenty of opportunities on the horizon, make sure to consider Horizon Therapeutics (HZNP).

Is Horizon Therapeutics (HZNP) a Great Growth Stock?

Horizon Therapeutics has now reached a growth point that is supportive of long-term success due to multiple eggs in the basket.

Horizon Therapeutics Will Offer Above Average Returns

Horizon (HZNP) beats on both earnings and revenues in Q2. Sales soared on account of the relaunch of the thyroid eye disease drug Tepezza.

Horizon's (HZNP) Q2 Earnings and Revenues Beat, Stock Up

Horizon Therapeutics Public Limited Company (HZNP) CEO Tim Walbert on Q2 2021 Results - Earnings Call Transcript

Horizon Therapeutics plc (NASDAQ: HZNP) stock is gaining amid second-quarter solid earnings after reporting adjusted EPS of $1.62, almost tripled from $0.40 posted a year ago, and easily beating the consensus of $$0.88 Net sales reached $832.5 million, +80% Y/Y, surpassing the consensus of $685.03 million.

Horizon Therapeutics Stock Shoots Higher As Relaunch Of Thyroid Eye Disease Med Boosts Q2 Sales; Raises FY21 Outlook

Horizon Therapeutics (HZNP) delivered earnings and revenue surprises of 78.02% and 17.76%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the stock?

Horizon Therapeutics (HZNP) Q2 Earnings and Revenues Beat Estimates

Shares of Horizon Therapeutics (NASDAQ:HZNP) moved higher by 9.0% in pre-market trading after the company reported Q2 results. Quarterly Results Earnings per share were up 305.00% year over year to $1.62, which beat the estimate of $0.88.

Horizon Therapeutics: Q2 Earnings Insights

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance

Horizon Therapeutics plc Reports Record Second-Quarter 2021 Financial Results; Increasing Full-Year 2021 Net Sales and Adjusted EBITDA Guidance

Adobe

Alibaba

Salesforce

Energy Transfer LP Unit

Shaw Communications

S&P Global

TAL Education Group

Autodesk

Microsoft

Analysts' reports can be an easy way to gauge market sentiment, particularly if you are confused regarding which stocks to buy. The post 10 Promising Stocks to Buy That Are Getting Lots of Analyst Love appeared first on InvestorPlace.

10 Promising Stocks to Buy That Are Getting Lots of Analyst Love

Horizon Therapeutics (HZNP) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Horizon Therapeutics (HZNP) Reports Next Week: Wall Street Expects Earnings Growth

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has been named to the 2021 Fortune Best Workplaces for Millennials™ list for the second consecutive year. Horizon ranked 16th out of 100 large companies. “We are proud that Fortune has recognized our millennial colleagues who now make up 35% of our workforce and contribute daily to the success of our company,” said Tim Walbert, chairman, president and chief executive officer, Horizon. “At Horizon, we go to

Fortune Names Horizon Therapeutics One of the 2021 Best Workplaces for Millennials™

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) announced today that its second-quarter 2021 financial results will be released on Wednesday, Aug. 4, 2021. Following the announcement, Horizon's management will host a live webcast at 8 a.m. Eastern Time to review the Company's financial and operating results. The live webcast and a replay may be accessed at http://ir.horizontherapeutics.com. Please connect to the Company's website at least 15 minutes prior to the live webcast to

Horizon Therapeutics plc to Release Second-Quarter 2021 Financial Results and Host Webcast on Aug. 4, 2021

Horizon (HZNP) starts phase II study to evaluate HZN-7734, an antibody to treat systemic lupus, which is an autoimmune disease wherein the immune system mistakenly attacks healthy cells and tissues.

Horizon (HZNP) Begins Phase II Study for Lupus Candidate

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it will host a virtual R&D Day for investors and analysts on Wednesday, Sept. 29, 2021 at 8 a.m. CT. Horizon's R&D Day will include presentations from the Company's R&D leadership team and key opinion leaders with a focus on the Company's pipeline. Additional details, including how to access the live webcast, will follow closer to the event. A recorded archived version of the webcast will be availa

Horizon Therapeutics plc to Host Virtual R&D Day on Sept. 29, 2021

If production setbacks can be avoided, gains should be in sight.

This Therapeutics Company Is Eyeing Zero Competition for the Next 5 Years

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in a Phase 2 trial to evaluate its development-stage medicine HZN-7734 (formerly VIB7734), a first-in-class, fully human monoclonal antibody targeting immunoglobulin-like transcript 7 (ILT7), to treat people with moderate to severely active systemic lupus erythematosus (SLE). SLE, which accounts for 70 percent of lupus cases1, is an autoimmune disease in which the immune system mistak

Horizon Therapeutics plc Announces First Patient Enrolled in Phase 2 Trial Evaluating HZN-7734 for the Treatment of Systemic Lupus Erythematosus

Arrowhead Pharmaceuticals

Arrowhead Pharmaceuticals Inc (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) have entered into a global collaboration and license agreement for ARO-XDH for uncontrolled gout. Horizon will pay $40 million upfront for global rights to Arrowhead Pharmaceuticals' ARO-XDH, an investigational RNAi therapy.

Horizon Acquires Rights to Arrowhead's RNAi-Based Gout Treatment Candidate

PASADENA, Calif. & DUBLIN--(BUSINESS WIRE)--Arrowhead Pharmaceuticals Inc. (NASDAQ: ARWR) and Horizon Therapeutics plc (NASDAQ: HZNP) today announced a global collaboration and license agreement for ARO-XDH, a previously undisclosed discovery-stage investigational RNA interference (RNAi) therapeutic being developed by Arrowhead as a potential treatment for people with uncontrolled gout. Gout is a serious and painful form of arthritis that is caused by excess uric acid in the blood. In the Unite

Arrowhead Pharmaceuticals and Horizon Therapeutics Announce Collaboration to Develop RNAi Therapeutic for Uncontrolled Gout

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the presentation of company information on Neuromyelitis Optica Spectrum Disorder (NMOSD) in three oral sessions during the 7th Congress of the European Academy of Neurology (EAN), June 19 -22, 2021. Presentations will discuss information from the open-label extension period (OLP) of the pivotal N-MOmentum trial for people living with NMOSD. “NMOSD is a chronic disease that requires lifelong management,” said Quinn

Horizon Therapeutics plc Announces Multiple Presentations on Neuromyelitis Optica Spectrum Disorder (NMOSD) at the 7th Congress of the European Academy of Neurology (EAN)

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced that it has reached an agreement to purchase a drug product manufacturing facility from EirGen Pharma, an OPKO Health Company (Nasdaq: OPK) in Waterford, Ireland. The facility, which is located in an IDA Ireland business park, includes a filling line and lyophiliser, or freeze dryer, that can be used for both Horizon's commercial medicines, including its rare disease biologics TEPEZZA (teprotumumab-trbw), KRYSTEXXA

Horizon Therapeutics plc Announces Purchase of Manufacturing Facility to Support Growth of On-Market Rare Disease and Pipeline Biologics

Horizon Therapeutics (HZNP) Down 1.8% Since Last Earnings Report: Can It Rebound?

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today presented new data during the EULAR European Congress of Rheumatology from the ongoing PROTECT study, which provides further insight into utility of KRYSTEXXA (pegloticase injection) as a treatment for people with uncontrolled gout (chronic gout refractory to conventional therapies) who have undergone a kidney transplant. The Prospective Study of Pegloticase in Transplant patients (PROTECT) trial is an ongoing Phase 4, multi

Horizon Therapeutics plc Presents New Data on Robust Pipeline at EULAR European Congress of Rheumatology

DUBLIN--(BUSINESS WIRE)--Horizon Therapeutics plc (Nasdaq: HZNP) today announced the first patient has enrolled in the ADVANCE trial evaluating the concomitant use of KRYSTEXXA (pegloticase injection) with methotrexate for people with uncontrolled gout who were not able to achieve a complete response when previously treated with KRYSTEXXA monotherapy. For people with chronic gout refractory to conventional therapies (uncontrolled gout), KRYSTEXXA offers a unique mechanism of action that convert

Horizon Therapeutics plc Initiates ADVANCE Trial Evaluating KRYSTEXXA® (pegloticase injection) with Methotrexate for People Who Previously Developed Anti-Drug Antibodies on KRYSTEXXA Monotherapy

News for Horizon Pharma Stock (HZNP)